Krsnaa Diagnostics Limited

As of June 30, 2026, Krsnaa Diagnostics Limited carries a market capitalization of 17.74B, placing it among publicly traded companies globally. Its enterprise value stands at 17.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Krsnaa Diagnostics Limited's next confirmed earnings release is scheduled for November 14, 2026.

As of June 30, 2026, Krsnaa Diagnostics Limited has 32.44M shares outstanding.

As of June 30, 2026, Krsnaa Diagnostics Limited trades at a trailing price-to-earnings ratio of 18.19.

As of June 30, 2026, Krsnaa Diagnostics Limited trades at an EV/EBITDA multiple of 8.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 17.74B versus a market cap of 17.74B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 1.36M in revenue per employee across its workforce of 5,977.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Krsnaa Diagnostics Limited recorded 279.21M in income tax expense. That works out to an effective tax rate of 22.27, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.25B, leaving 974.60M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Krsnaa Diagnostics Limited's stock has declined approximately 36.19% over the past 52 weeks. The 50-day moving average sits at 549.72, while the 200-day moving average is 590.65.

Over the twelve months ended June 30, 2026, Krsnaa Diagnostics Limited generated 8.15B in revenue and converted that into 974.60M in net income, yielding earnings per share of 29.66. EBITDA reached 2.18B, while operating income came in at 1.22B.

Over the twelve months ended June 30, 2026, Krsnaa Diagnostics Limited posted a gross margin of 67.04, reflecting its pricing power and cost economics. The operating margin of 14.92 and net profit margin of 11.95 provide insight into operational efficiency.